secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-114905
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Q3 2023: PEDMARK revenue $6.5M (+96% QoQ); UK approval for PEDMARQSI
---------------------------------------------------------------------------

- PEDMARK net product revenue $6.5M in Q3 2023, up 96% from $3.3M in Q2 2023.
- Net loss narrowed to $1.9M ($0.07/share) from $8.1M ($0.31) in Q3 2022.
- Received UK MHRA approval for PEDMARQSI in October 2023.
- Cash and equivalents $12.4M at Sept 30, 2023; sufficient for at least 12 months.
- Gross profit $6.2M; selling & marketing expenses $3.4M for U.S. and EU launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/0001104659-23-114905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923114905/tm2330040d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer